183500-94-9

Usage

Uses

Used in Pharmaceutical Research:
1-(3-Chlorophenyl)piperazin-2-one hydrochloride is used as a research compound for studying its effects on neurotransmitter systems and exploring its potential as a treatment for various mental health conditions. Its psychoactive properties have been of interest in understanding its impact on the central nervous system.
Used in Psychopharmacological Studies:
In psychopharmacological research, 1-(3-Chlorophenyl)piperazin-2-one hydrochloride is used as a test substance to investigate its potential therapeutic effects on conditions such as anxiety, depression, and schizophrenia. The aim is to uncover its mechanisms of action and evaluate its safety and efficacy in comparison to existing treatments.

Upstream product

• 183500-69-8 4-(tert-butoxycarbonyl)-1-(3-chlorophenyl)-2-piperazinone 
• 108-42-9 3-chloro-aniline 
• 2564-05-8 2-chloro-N-(3-chlorophenyl)acetamide 
• 215649-70-0 N¹-(3-chlorophenyl)-N²-(2-hydroxyethyl)glycinamide 

Relevant academic research and scientific papers

Synthesis and cytotoxicity evaluation of some novel 1-(3-Chlorophenyl) piperazin-2-one derivatives bearing imidazole bioisosteres

A series of substituted 3-chlorophenylpiperazinone derivatives were synthesised using L-778123 (an imidazole-containing FTase inhibitor) as a model by bioisosteric replacement of the imidazole ring. The final compounds were evaluated against two human cancer cell lines including A549 (lung cancer) and HT-29 (colon cancer) by MTT assay. The results showed that substitution of imidazole ring with 1-amidinourea, semicarbazide, and thiobiuret led to improvement of cytotoxic activity against both cell lines.

Method of treating cancer

The present invention relates to methods of treating cancer using a combination of a compound which is an antineoplastic agent and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either s

Preparation of a clinically investigated ras farnesyl transferase inhibitor

The synthesis of ras farnesyl-protein transferase inhibitor 1 is described on a multi-kilogram scale. Retrosynthetic analysis reveals chloromethylimidazole 2 and a piperazinone 3 as viable precursors. The 1,5-disubstituted imidazole system was regioselectively assembled via an improved Marckwald imidazole synthesis. A new imidazole dethionation procedure has been developed to convert the Marckwald mercaptoimidazole product to the desired imidazole. This methodology was found to be tolerant of a variety of functional groups providing good to excellent yields of 1,5-disubstituted imidazoles. A new Mitsunobu cyclization strategy was developed to prepare the arylpiperazinone fragment 3.

Inhibitors of prenyl-protein transferase

The present invention comprises piperazinone-containing compounds, which may be useful as inhibitors of prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.

Sustained release drug dispersion delivery device

The present invention is related to a drug delivery device, that is pH insensitive, for the sustained in situ production and release of a dispersion, in an environment of use, which comprises a) a compressed core prepared from an admixture comprising i) a

Process for the synthesis of substituted piperazinones via Mitsunobu reaction

The present invention is directed to a process for synthesizing substituted piperazinones, which are useful intermediates for making farnesyl-protein transferase inhibitors, using a Mitsunobu reaction.

Efficient synthesis of N-arylpiperazinones via a selective intramolecular Mitsunobu cyclodehydration

A practical two pot synthesis of N-arylpiperazinones from the corresponding aniline is described. The key transformation is a selective intramolecular Mitsunobu cyclodehydration of an amidoalcohol intermediate. A series of N-arylpiperazinones were prepared in yields up to 89%.